FDA: Genitope must continue vaccine tests
Genitope's hopes of bringing its MyVax cancer vaccine to market quickly were dashed Monday when an independent board recommended that a clinical trial of its cancer vaccine continue. Although the 300-patient trial was scheduled to end in 2007, Genitope believed its vaccine might produce results sooner. The vaccine for an incurable form of non-Hodgkin's lymphoma, a blood cancer, is Genitope's most advanced product. The news took a bite out of its stock value this morning.
- read this story from the Los Angeles Times for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
